A new collaborative study published in the Journal of Nuclear Medicine found that a blood-based tumour DNA test, used alongside PSMA PET scans, could help predict which patients are most likely to benefit from a combination of radioligand therapy and immunotherapy and provide an early indication of whether the treatment is working.








